Download PDF
Thromb Haemost 2002; 88(03): 376-377
DOI: 10.1055/s-0037-1613224
Commentary
Schattauer GmbH

The 1st International Standard for von Willebrand Factor Concentrate: More to Come?

Hans P. Schwarz
1   Baxter BioScience, Vienna, Austria
,
Bruce Ewenstein
2   Baxter BioScience, Glendale, California, USA
,
Peter L. Turecek
1   Baxter BioScience, Vienna, Austria
› Author Affiliations
Further Information

Publication History

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
    CrossrefPubMedSearch in Google Scholar
  • 2 Ruggeri ZM. Developing basic and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost 2000; 84: 147-9.
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
    PubMedSearch in Google Scholar
  • 4 Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsberg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97: 1915-9.
    CrossrefPubMedSearch in Google Scholar
  • 6 Chang AC, Rick ME, Ross LPierce, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 04 (Suppl. 03) 1-6.
    CrossrefPubMedSearch in Google Scholar
  • 7 Campbell PJ. International biological standards and reference preparations. J Biol Stand 1974; 02: 249-58.
    CrossrefPubMedSearch in Google Scholar
  • 8 Hubbard AR, Sands D, Chang AC, Mazurier C. Standardisation of von Willebrand factor in therapeutic concentrates: calibration of the 1st International standard for von Willebrand factor concentrate (00/514). Thromb Haemost 2002; 88: 380-6.
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 2001; 07 (Suppl. 01) 10-5.
    CrossrefPubMedSearch in Google Scholar
  • 10 Favaloro EJ, Bukuya M, Martinelli T, Tzouroutis J, Duncan E, Welldon K, Collecut M, Aumann H, Thorn J, Gilmore G. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates. Thromb Haemost 2002; 87: 466-76.
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia 1998; 04: 634-40.
    CrossrefPubMedSearch in Google Scholar
  • 12 Neugebauer BM, Goy C, Budek I, Seitz R. Comparison of Two von Willebrand Factor Collagen-Binding Assays with different Binding Affinities for Low, Medium, and High Multimers of von Willebrand Factor. Semin Thromb Hemost 2002; 08: 139-47.
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Neugebauer BM, Volkers P, Seitz R. von Willebrand factor potency determination by collagen binding assay. A collaborative study for the establishment of a European Pharmacopoeia Method. Pharmeuropa 2002; 14: 315-22.
    PubMedSearch in Google Scholar